News Headlines
-
Imugene And Kincell Bio Announce Strategic Manufacturing And Process Development Partnership
4/16/2024
Imugene, Ltd. (“Imugene”)(ASX: IMU) and Kincell Bio, LLC (“Kincell”), announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice (CGMP) manufacturing facility and the transfer of process and analytical development activities to Kincell.
-
AmplifyBio And RNAV8 Bio Announce Strategic Partnership To Support mRNA Therapeutic Developers From Sequence Design To GMP Manufacture
4/16/2024
AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics.
-
BioHarvest Sciences Announces New Campus For Botanical Synthesis CDMO And Expansion Of Manufacturing Capacity
4/16/2024
BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) a biotechnology company pioneering its patented Botanical Synthesis technology process, today announced the signing of two agreements: a long term lease agreement for a new 80,000 square ft. facility in Yavne, Israel, and an equipment purchase agreement for 12 state of the art GMP clean rooms.
-
Medincell Enters Into Strategic Co-Development And Licensing Agreement With Abbvie To Develop Next-Generation Long-Acting Injectable Therapies
4/16/2024
Medincell today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications.
-
NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement To Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials
4/10/2024
NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the signing of a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials.
-
Asahi Kasei Bioprocess And Axolabs Announce Strategic Partnership To Accelerate Oligonucleotide Therapeutics Development
4/10/2024
Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics.
-
ChromaTan And Batavia Receive NIIMBL Grant To Integrate Column-Free Steady-State Continuous Elution Chromatography Into HIP-Vax Manufacturing Platform For AAV
4/10/2024
ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce an alliance with Batavia Biosciences, a leading contract development and manufacturing organization, for the development and integration of ChromaTan’s BioRMBTM continuous counter-current elution technology into Batavia’s AAV HIP-Vax manufacturing platform.
-
Ascend Acquires GMP Manufacturing Capacity In Alachua, Florida; Enters Long-Term Partnership With Beacon Therapeutics For Clinical And Commercial AAV Production
4/9/2024
Ascend Advanced Therapies (Ascend), a total solutions gene therapy development partner, has acquired the CMC team and site in Alachua, Florida from Beacon Therapeutics (Beacon). The transaction brings an operational good manufacturing practice (GMP) facility, process and analytical development capabilities, and additional experts to the Ascend team. It also includes a long-term partnership with Beacon to continue manufacturing its products for clinical and commercial use, securing product supply for Beacon and enabling it to focus on clinical development.
-
Virtuosi Becomes An IACET Accredited Provider
4/9/2024
The International Accreditors for Continuing Education and Training (IACET) has awarded Virtuosi the prestigious Accredited Provider accreditation.
-
Charles River Announces Rare Disease Gene Therapy Collaboration With Axovia Therapeutics
4/9/2024
Charles River Laboratories International, Inc. today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.